July 24, 2023 07:19 AM EDT
R&D

Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Amber Tong

Gilead will scrap one of three Phase III tri­als for ma­grolimab, the an­ti-CD47 drug at the heart of its $4.9 bil­lion ac­qui­si­tion of Forty Sev­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times